Meta-Analysis Comparing Rosuvastatin and Atorvastatin in Reducing Concentration of C-Reactive Protein in Patients With Hyperlipidemia

Abstract

We conducted a meta-analysis of 13 randomized trials comparing the efficacy of rosuvastatin versus atorvastatin in reducing concentrations of C-reactive protein (CRP). We searched PubMed, Ovid, and Elsevier databases until June 2014. Search terms included C-reactive protein or CRP, rosuvastatin, atorvastatin, randomized, randomly, and randomization; 13 trials (3798 patients) were included. Funnel plots for CRP were inspected to assess publication bias. The pooled analysis demonstrated the benefit of rosuvastatin over atorvastatin therapy for all 13 trials (mean difference [MD] = -0.11, which is standardized mean with no unit although the raw data before pooling is mg/L, 95% confidence interval -0.15 to -0.07, P < .0001) with no evidence of significant publication bias (I(2) = 6.9%, P = .377). Subgroup analysis indicated a significant benefit of rosuvastatin over atorvastatin regarding the 1/1 dose ratio (MD = -0.14, 95% CI -0.21 to -0.06) and 1/2 dose ratio (MD= -0.11, 95% CI -0.16 to -0.05). Cumulative and influence analyses showed accuracy and stability for the estimation mentioned earlier. Our meta-analysis shows that rosuvastatin produces better reduction in CRP concentrations than atorvastatin at a dose ratio of 1/1 and 1/2 (rosuvastatin/atorvastatin), respectively.

1.2% Rosuvastatin Versus 1.2% Atorvastatin Gel Local Drug Delivery and Redelivery in Treatment of Intrabony Defects in Chronic Periodontitis: A Randomized Placebo‐Controlled Clinical Trial

“…The significance of clinical benefits with RSV over ATV might be explained by greater anti-inflammatory action with greater decrease in CRP levels with RSV than with ATV use. 26,27 RSV has also been found to be superior to ATV in the reversion of coronary atherosclerotic plaques 28 and in reduction of small, dense low-density lipoproteins. 29 Compared with ATV, simvastatin, and pravastatin, RSV has also been found to be superior in lowering low-density lipoprotein cholesterol, 30,31 providing greater health benefits, besides being more cost-effective.…”

“…The significance of clinical benefits with RSV over ATV might be explained by greater anti‐inflammatory action with greater decrease in CRP levels with RSV than with ATV use 26 , 27 . RSV has also been found to be superior to ATV in the reversion of coronary atherosclerotic plaques 28 and in reduction of small, dense low‐density lipoproteins 29 .…”

Anti-inflammatory effects of rosuvastatin treatment in coronary artery ectasia patients in different age groups

“…The anti-in ammatory and endotheliumprotective effects of rosuvastatin have been suggested to improve symptoms in patients with coronary artery disease. We chose rosuvastatin because it has stronger anti-in ammatory and antioxidant activity than atorvastatin [11]. However, there is no conclusive evidence of the therapeutic e cacy or optimal timepoint for rosuvastatin therapy in CAE patients in different age groups.…”

Rosuvastatin promotes benefits on induced periodontitis in hypertensive rats

“…To the best of our knowledge, there are no studies evaluating the effects of statins on periodontitis associated with hypertension. Compared with other types of statins, ST have been demonstrating greater anti‐inflammatory action and superior potential in lowering low‐density lipoprotein cholesterol , providing greater health benefits, besides being more cost‐effective . In this context, the aim of this study was to evaluate the effects of ST on ligature‐induced periodontitis in SHR through examining bone loss by histometric analysis, osteoclastogenesis by tartrate‐resistant acid phosphatase (TRAP) assay and gene expression of proinflammatory molecules in gingiva using polymerase chain reaction (PCR).…”